{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:05:13Z","timestamp":1772294713833,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T00:00:00Z","timestamp":1527897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00520-018-4292-0","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T08:58:20Z","timestamp":1527929900000},"page":"4187-4198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001\u20132005 using the Japan Adult Leukemia Study Group AML201 protocols"],"prefix":"10.1007","volume":"26","author":[{"name":"Japan Adult Leukemia Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-6863","authenticated-orcid":false,"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobu","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shigeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Miyatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,2]]},"reference":[{"key":"4292_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56\u2013e93. \n                    https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"key":"4292_CR2","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"4292_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","volume":"16","author":"EA Engels","year":"1998","unstructured":"Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179\u20131187. \n                    https:\/\/doi.org\/10.1200\/JCO.1998.16.3.1179","journal-title":"J Clin Oncol"},{"key":"4292_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1200\/JCO.1996.14.1.204","volume":"14","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R (2012) Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance\/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 14:204\u2013213. \n                    https:\/\/doi.org\/10.1200\/JCO.1996.14.1.204","journal-title":"J Clin Oncol"},{"key":"4292_CR5","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1002\/1097-0142(19930615)71:12<3888::AID-CNCR2820711216>3.0.CO;2-G","volume":"71","author":"R Ohno","year":"1993","unstructured":"Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y, Yoshida M, Murakami H, Naoe T, Shimoyama M, Tsukada T, Takeo T, Teshima H, Onozawa Y, Fujimoto K, Kuriyama K, Horiuchi A, Kimura I, Minami S, Miura Y, Kageyama S, Tahara T, Masaoka T, Shirakawa S, Saito H (1993) Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). Cancer 71:3888\u20133895","journal-title":"Cancer"},{"key":"4292_CR6","first-page":"97","volume":"70","author":"S Miyawaki","year":"1999","unstructured":"Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R (1999) No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 70:97\u2013104","journal-title":"Int J Hematol"},{"key":"4292_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12185-009-0480-5","volume":"91","author":"S Ohtake","year":"2010","unstructured":"Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R (2010) Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol 91:276\u2013283. \n                    https:\/\/doi.org\/10.1007\/s12185-009-0480-5","journal-title":"Int J Hematol"},{"key":"4292_CR8","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/cncr.21493","volume":"104","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study (2005) A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia. Cancer 104:2726\u20132734. \n                    https:\/\/doi.org\/10.1002\/cncr.21493","journal-title":"Cancer"},{"key":"4292_CR9","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood 117:2358\u20132366. \n                    https:\/\/doi.org\/10.1182\/blood-2010-03-273243","journal-title":"Blood"},{"key":"4292_CR10","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. Blood 117:2366\u20132373. \n                    https:\/\/doi.org\/10.1182\/blood-2010-07-295279","journal-title":"Blood"},{"key":"4292_CR11","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1086\/383044","volume":"39","author":"M Yoshida","year":"2004","unstructured":"Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39:S11\u2013S14. \n                    https:\/\/doi.org\/10.1086\/383044","journal-title":"Clin Infect Dis"},{"key":"4292_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12185-009-0367-5","volume":"90","author":"H Fujita","year":"2009","unstructured":"Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N, Ohnishi K, Miyawaki S, Naoe T (2009) Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan adult leukemia study group. Int J Hematol 90:191\u2013198. \n                    https:\/\/doi.org\/10.1007\/s12185-009-0367-5","journal-title":"Int J Hematol"},{"key":"4292_CR13","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1007\/s00520-017-3775-8","volume":"25","author":"S Kimura","year":"2017","unstructured":"Kimura S, Fujita H, Kato H et al (2017) Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. Support Care Cancer 25:3515\u20133521. \n                    https:\/\/doi.org\/10.1007\/s00520-017-3775-8","journal-title":"Support Care Cancer"},{"key":"4292_CR14","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39:S49\u2013S52. \n                    https:\/\/doi.org\/10.1086\/383054","journal-title":"Clin Infect Dis"},{"key":"4292_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12185-010-0746-y","volume":"93","author":"M Yoshida","year":"2011","unstructured":"Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake JI, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T (2011) Analysis of bacteremia\/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 93:66\u201373. \n                    https:\/\/doi.org\/10.1007\/s12185-010-0746-y","journal-title":"Int J Hematol"},{"key":"4292_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004386.pub3","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LCM, Leibovici L, Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386. \n                    https:\/\/doi.org\/10.1002\/14651858.CD004386.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4292_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/stem.1140","volume":"30","author":"BK Hamilton","year":"2012","unstructured":"Hamilton BK, Copelan EA (2012) Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. Stem Cells 30:1581\u20131586. \n                    https:\/\/doi.org\/10.1002\/stem.1140","journal-title":"Stem Cells"},{"key":"4292_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-010-0984-1","volume":"29","author":"H Syrj\u00e4l\u00e4","year":"2010","unstructured":"Syrj\u00e4l\u00e4 H, Ohtonen P, Kinnunen U et al (2010) Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29:1211\u20131218. \n                    https:\/\/doi.org\/10.1007\/s10096-010-0984-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4292_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1128\/CMR.00109-13","volume":"27","author":"K Becker","year":"2014","unstructured":"Becker K, Heilmann C, Peters G (2014) Coagulase-negative staphylococci. Clin Microbiol Rev 27:870\u2013926. \n                    https:\/\/doi.org\/10.1128\/CMR.00109-13","journal-title":"Clin Microbiol Rev"},{"key":"4292_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/502539","volume":"26","author":"C Muto","year":"2005","unstructured":"Muto C, Pokrywka M, Shutt K et al (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26:273\u2013280","journal-title":"Infect Control Hosp Epidemiol"},{"key":"4292_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/1471-2334-13-356","volume":"13","author":"M Garnica","year":"2013","unstructured":"Garnica M, Nou\u00e9r SA, Pellegrino FLPC et al (2013) Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis 13:356. \n                    https:\/\/doi.org\/10.1186\/1471-2334-13-356","journal-title":"BMC Infect Dis"},{"key":"4292_CR22","unstructured":"Ministry of Health, Labor and Welfare (2015) Japan Nosocomial Infections Surveillance [in Japanese]. \n                    https:\/\/janis.mhlw.go.jp\/report\/open_report\/2016\/3\/1\/ken_Open_Report_201600.pdf\n                    \n                   Accessed on 25 Dec 2017"},{"key":"4292_CR23","unstructured":"Ministry of Health, Labor and Welfare (2005) Japan Nosocomial Infections Surveillance [in Japanese]. \n                    https:\/\/janis.mhlw.go.jp\/report\/season\/nenpou\/2005\/ken_note.html\n                    \n                   Accessed on 25 Dec 2017"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4292-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:40:18Z","timestamp":1559439618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4292-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,2]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4292"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4292-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,2]]},"assertion":[{"value":"28 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hideaki Kato received grants from Japan Blood Products Organization and Shionogi. Hiroyuki Fujita received honoraria from Novartis, and payment for manuscripts from Chugai Pharmaceutical. Shun-ichi Kimura received honoraria from Pfizer, Astellas, Sumitomo Dainippon Pharma, and Nippon Kayaku. Tsutomu Takahashi received grants from Chugai Pharmaceutical, Kyowa Hakko Kirin, and Astellas, honoraria from Chugai Pharmaceutical, Kyowa Hakko Kirin, Taiho Pharmaceutical and Celgene Corporation. Junichi Miyatake received honoraria from Kyowa Hakko Kirin, Celgene Corporation, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Chugai Pharmaceutical. Hiroshi Handa received consulting fee from Takeda Pharmaceutical and Celgene Corporation, grants and honoraria from Celgene Corporation, Takeda Pharmaceutical, Pfizer, Astellas, Sanofi, MSD, Shionogi, Daiichi Sankyo, Kyowa Hakko Kirin, Novartis, and Shire. Shunichi Miyawaki received a consulting fee from Astellas and expert testimony from Ohtsuka Pharmaceutical and Novartis. Hitoshi Kiyoi received consulting fees from Astellas and Daiichi Sankyo, grants from Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin, Zenyaku Kogyo, FUJIFILM Corporation, Nippon Boehringer Ingelheim, Astellas and Celgene Corporation, and honoraria from Bristol-Myers Squibb and Pfizer. Other authors: none to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}